MARKET

XOMA

XOMA

Xoma Corp Del
NASDAQ

Real-time Quotes | Nasdaq Last Sale

17.26
-0.61
-3.41%
After Hours: 17.26 0 0.00% 16:00 05/24 EDT
OPEN
17.72
PREV CLOSE
17.87
HIGH
18.06
LOW
17.06
VOLUME
35.42K
TURNOVER
0
52 WEEK HIGH
39.02
52 WEEK LOW
16.96
MARKET CAP
197.13M
P/E (TTM)
31.95
1D
5D
1M
3M
1Y
5Y
XOMA to Present at H.C. Wainwright Global Investment Conference
EMERYVILLE, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA), a biotechnology royalty aggregator playing a distinctive role in helping companies achieve their goal of improving human health, announced today its Chairman and Chief Ex...
GlobeNewswire · 05/17 20:05
Recap: XOMA Q1 Earnings
  XOMA (NASDAQ:XOMA) reported its Q1 earnings results on Thursday, May 5, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Benzinga · 05/05 13:03
Xoma (XOMA) Reports Q1 Loss, Misses Revenue Estimates
Xoma (XOMA) delivered earnings and revenue surprises of 5.88% and 12.73%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/05 12:55
XOMA GAAP EPS of -$0.32 beats by $0.21, revenue of $3.11M misses by $0.06M
XOMA press release (NASDAQ:XOMA): Q1 GAAP EPS of -$0.32 beats by $0.21. Revenue of $3.11M (+718.4% Y/Y) misses by $0.06M. Ended the first quarter of 2022 with cash and restricted
Seekingalpha · 05/05 12:53
BRIEF-XOMA Reports First Quarter 2022 Financial Results
reuters.com · 05/05 11:39
-- Earnings Flash (XOMA) XOMA CORPORATION Posts Q1 Revenue $3.1M
MT Newswires · 05/05 07:45
Kymera Therapeutics, Inc. (KYMR) Reports Q1 Loss, Lags Revenue Estimates
Kymera Therapeutics, Inc. (KYMR) delivered earnings and revenue surprises of -5.97% and 44.58%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/03 12:15
What Is The Ownership Structure Like For XOMA Corporation (NASDAQ:XOMA)?
If you want to know who really controls XOMA Corporation ( NASDAQ:XOMA ), then you'll have to look at the makeup of its...
Simply Wall St. · 04/20 12:24
More
No Data
Learn about the latest financial forecast of XOMA. Analyze the recent business situations of Xoma Corp Del through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
66.67%Buy
33.33%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average XOMA stock price target is 62.50 with a high estimate of 69.00 and a low estimate of 56.00.
High69.00
Average62.50
Low56.00
Current 17.26
EPS
Actual
Estimate
0.160.831.502.17
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 81
Institutional Holdings: 6.89M
% Owned: 60.29%
Shares Outstanding: 11.42M
TypeInstitutionsShares
Increased
14
103.21K
New
6
34.02K
Decreased
16
67.06K
Sold Out
3
10.74K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.05%
Pharmaceuticals & Medical Research
+0.25%
Key Executives
Chairman/Chief Executive Officer/Director
James Neal
Chief Financial Officer/Senior Vice President - Finance
Thomas Burns
Lead Director/Independent Director
W. Denman Van Ness
Independent Director
Heather Franklin
Independent Director
Natasha Hernday
Independent Director
Barbara Kosacz
Independent Director
Joseph Limber
Independent Director
Matthew Perry
Independent Director
Jack Wyszomierski
No Data
No Data
About XOMA
XOMA Corporation (XOMA) is a biotechnology royalty aggregator. The Company's drug royalty aggregator business is focused on early to mid-stage clinical assets primarily in Phase I and II. XOMA acquires pre-commercial therapeutic candidates that are licensed to pharmaceutical or biotechnology companies. The Company's portfolio of partner-funded programs spans multiple stages of the drug development process and across various therapeutic areas. The Company's royalty-aggregator business includes acquiring additional licenses to programs with third-party funding and has more than 70 assets. XOMA royalty portfolio includes NIS793, anti-transforming growth factor-beta (TGFb) antibody program; gevokizumab (VPM087); mezagitamab (TAK-079), iscalimab (CFZ533), and MK-4830.

Webull offers kinds of XOMA Corp stock information, including NASDAQ:XOMA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, XOMA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading XOMA stock methods without spending real money on the virtual paper trading platform.